Pediatrix Medical Group, Inc. MD

Healthcare SIC 8060 - Services-Hospitals NAICS Health Care and Social Assistance › Hospitals derived NYSE

Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. During 2024, we formalized our practice portfolio management plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. As of December 31, 2024, these plans were completed. Additionally, we exited our primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale. At December 31, 2025, our national network comprised approximately 2,295 affiliated physicians, including 1,350 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units ("NICUs"), to babies born prematurely or with medical complications. We have over 475 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including over 230 physicians providing pediatric intensive care, 220 physicians providing hospital-based pediatric care, and 20 physicians providing pediatric surgical care.

Last close 29.29 2026-10-23
Market cap $2.38B 2026-06-30 share count
52-week range 16.90 - 29.70

Valuation FY2025 figures against the last close

P/S1.2x
P/E15.1x
P/FCF8.8x
EV/EBITDA10.3x
Dividend yield—
Diluted EPS1.94

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.91B$2.01B$1.99B$1.97B$1.91B$1.73B$1.78B$1.72B$3.25B$3.18B
SG&A $240.8M$238.4M$227.5M$231.4M$263.4M$248.9M$244.5M$232.2M$385.9M$372.6M
Total operating expenses $1.71B$2.08B$1.99B$1.80B$1.71B$1.64B$1.61B$1.47B$2.80B$2.61B
Operating income $208.8M-$68.7M$7.3M$172.7M$202.9M$98.1M$171.8M$248.4M$454.9M$571.7M
Interest expense $36.0M$40.7M$42.1M$39.7M$68.7M$110.5M$118.9M$92.9M$74.6M$63.1M
Pre-tax income $216.4M-$101.3M-$48.4M$81.4M$135.2M$7.1M$58.8M$166.2M$385.7M$513.8M
Income tax $51.0M$2.3M$12.0M$18.8M$27.2M$16.7M$16.6M$44.7M$80.2M$189.2M
Net income $165.4M-$99.1M-$60.4M$66.3M$131.0M-$796.5M-$1.50B$268.6M$320.4M$324.9M
EPS, basic 1.97-1.19-0.730.791.54-9.55-17.942.953.473.52
EPS, diluted 1.94-1.19-0.730.791.53-9.55-17.832.933.453.49
Shares, diluted (wtd. avg.) 85.3M83.3M82.2M84.1M85.8M83.4M84.0M91.6M93.0M93.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $375.2M$229.9M$73.3M$9.8M$387.4M$1.12B$107.9M$40.8M$40.4M$55.7M
Short-term investments $124.5M$118.6M$104.5M$93.2M$99.7M$104.9M$74.5M$21.9M——
Receivables $229.7M$260.0M$272.3M$296.8M$301.8M$241.9M$434.3M$506.7M$504.0M$495.3M
Total current assets $763.5M$639.6M$483.5M$428.0M$840.6M$1.55B$731.5M$660.0M$627.2M$587.1M
Property, plant and equipment $39.2M$39.2M$75.6M$73.3M$70.2M$76.2M$72.7M$90.4M$123.5M$103.1M
Goodwill $1.26B$1.24B$1.38B$1.53B$1.51B$1.48B$1.48B$4.06B$4.28B$3.85B
Other intangibles $16.9M$11.6M$21.2M$18.5M$21.6M$26.6M$28.6M$313.2M$639.9M$668.5M
Total assets $2.25B$2.15B$2.22B$2.35B$2.72B$3.35B$4.15B$5.94B$5.87B$5.34B
Accounts payable $37.2M$46.4M$34.6M$31.9M$36.6M$59.8M$35.4M$31.1M$34.6M$28.5M
Short-term debt —————————$20.0M
Total current liabilities $458.9M$434.1M$388.9M$427.0M$427.4M$444.3M$541.8M$502.8M$531.4M$448.9M
Long-term debt —$611.2M$622.2M$637.2M$989.7M$1.70B$1.70B$1.97B$1.85B$1.68B
Total liabilities $1.38B$1.39B$1.37B$1.46B$1.83B$2.60B$2.65B$2.85B$2.80B$2.58B
Retained earnings -$83.2M-$248.5M-$149.5M-$89.1M-$155.4M-$286.4M$510.1M$2.09B$2.05B$1.79B
Total equity $865.9M$764.9M$849.1M$891.6M$896.7M$747.7M$1.50B$3.09B$3.07B$2.76B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $271.1M$206.6M$137.3M$166.9M$76.7M$204.6M$357.7M$313.7M$511.4M$443.8M
Depreciation and amortisation $21.8M$32.2M$36.2M$35.6M$32.1M$28.4M$25.9M$24.4M$78.9M$89.3M
Stock-based compensation $18.0M$11.9M$12.3M$16.1M$19.0M$39.0M$33.4M$36.6M$28.8M$34.0M
Investing cash flow -$18.3M-$35.4M-$48.2M-$57.0M-$53.1M$815.5M$102.5M-$142.8M-$576.6M-$821.2M
Financing cash flow -$107.5M-$14.5M-$25.7M-$487.6M-$760.1M-$4.2M-$393.1M-$170.6M$89.7M$381.6M
Buybacks $86.7M$1.7M$919.0K$88.5M$4.7M$8.5M$145.3M$302.2M$70.2M$61.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-058074.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B 0 2B 4B Revenue, FY2016: 3.2B Net income, FY2016: 324.9M Revenue, FY2017: 3.3B Net income, FY2017: 320.4M Revenue, FY2018: 1.7B Net income, FY2018: 268.6M Revenue, FY2019: 1.8B Net income, FY2019: -1.5B Revenue, FY2020: 1.7B Net income, FY2020: -796.5M Revenue, FY2021: 1.9B Net income, FY2021: 131M Revenue, FY2022: 2B Net income, FY2022: 66.3M Revenue, FY2023: 2B Net income, FY2023: -60.4M Revenue, FY2024: 2B Net income, FY2024: -99.1M Revenue, FY2025: 1.9B Net income, FY2025: 165.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $3.18B $3.25B $1.72B $1.78B $1.73B $1.91B $1.97B $1.99B $2.01B $1.91B
Gross profit — — — — — — — — — —
Net income $324.9M $320.4M $268.6M -$1.50B -$796.5M $131.0M $66.3M -$60.4M -$99.1M $165.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8060

TickerCompanyMarket capP/ERevenue growth
EHC Encompass Health Corp $12.24B 22.4x 10.5%